Bookmark and Share
BioAssay: AID 1997

qHTS for Inhibitors of CDC-like Kinase 4: Summary

Alternative splicing of pre-mRNAs plays a major role in the regulation of eukaryotic gene expression. Alternative splicing is now thought to be one of the primary reasons for the complexity of higher organisms leading to an average of three protein isoforms per gene. Aberrant splicing can lead to a number of diseases and is known to play a role in rare genetic diseases such as progeria syndrome. more ..
_
   
 Tested Compounds
 Tested Compounds
All(29)
 
 
Probe(3)
 
 
Active(29)
 
 
 Tested Substances
 Tested Substances
All(29)
 
 
Probe(3)
 
 
Active(29)
 
 
AID: 1997
Data Source: NCGC (CLK905)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2009-10-20
Modify Date: 2011-09-07

Data Table ( Complete ):           Active    All
Target
Sequence: CDC-like kinase 4 [Homo sapiens]
Description ..   
Protein Family: Protein Kinases, catalytic domain

Gene:CLK4     Related Protein 3D Structures     More BioActivity Data..
BioActive Compounds: Chemical Probe: 3    Active: 29
Depositor Specified Assays
Show more
AIDNameTypeComment
493206Assay for Inhibitors of Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (Kinase-Glo assay): round 2 SARconfirmatoryDyrk 1A Panel Assay
1770qHTS Assay for Inhibitors of CDC-like Kinase 4 (Kinase-Glo Assay)confirmatoryClk4 inhibition primary assay (Kinase-Glo)
1771qHTS Assay for Inhibitors of CDC-like Kinase 4 (ADP-Glo Assay)confirmatoryClk4 inhibition primary assay (ADP-Glo)
1795qHTS Assay for Inhibitors of CDC-like Kinase 4 (ADP-FP Assay)confirmatoryClk4 inhibition primary assay (ADP-FP)
1969Confirmaiton Assay for Inhibitors of CDC-like Kinase 4 (ADP-Glo Assay)confirmatoryClk4 inhibition conformation assay (ADP-Glo)
1970Confirmation Assay for Inhibitors of CDC-like Kinase 4 (Kinase-Glo Assay)confirmatoryClk4 inhibition conformation assay (ATP-Glo)
1983Confirmation Assay for Inhibitors of CDC-like Kinase 4 (ADP-FP Assay)confirmatoryClk4 inhibition conformation assay (ADP-FP)
2705Assay for Inhibitors of Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (Kinase-Glo assay)confirmatoryClk4 inhibition secondary assay: Dyrk1a Kinase-Glo assay
2710Kinase Inhibition Profile Study on Inhibitors of CDC-like Kinase 4otherClk4 inhibition secondary assay: Reaction Biology selectivity panel assay
493204Confirmation Assay for Inhibitors of CDC-like Kinase 4 (Kinase-Glo Assay): SAR round 2confirmatory
504421Kinase Inhibition Study on Inhibitors of CDC-like Kinase 4 (Reaction Biology data): SAR round 2confirmatory
504424Kinase Inhibition Study on Inhibitors of Dyrk1a (Reaction Biology data)confirmatory
504427Kinase Inhibition Study on Inhibitors of CDC-like Kinase 2 (Reaction Biology data)confirmatory
504428Kinase Inhibition Study on Inhibitors of CDC-like Kinase 3 (Reaction Biology data)confirmatory
504429Kinase Inhibition Study on Inhibitors of Dyrk1b (Reaction Biology data)confirmatory
504430Kinase Inhibition Study on Inhibitors of CDC-like Kinase 1 (Reaction Biology data)confirmatory
504534Secondary Assay for Inhibitors of Human Cdc-like kinase 4 (Clk4): HEK-293 Cell Viability Assayconfirmatory
624034Reaction Biology data for inhibitors of CLK4: Probe SARconfirmatory
624045Reaction Biology data for inhibitors of DYRK1A: Probe SARconfirmatory
624046Reaction Biology data for inhibitors of DYRK1B: Probe SARconfirmatory
624047Reaction Biology data for inhibitors of CLK1: Probe SARconfirmatory
624048Reaction Biology data for inhibitors of CLK2: Probe SARconfirmatory
624049Reaction Biology data for inhibitors of CLK3: Probe SARconfirmatory
624093Confirmation Assay for Inhibitors of Dyrk1a (Kinase-Glo Assay): KU probeconfirmatory
624094Confirmation Assay for Inhibitors of Clk4 (Kinase-Glo Assay): KU probeconfirmatory
Description:
NIH Molecular Libraries Probe Production Centers Network [MLPCN]
NIH Chemical Genomics Center [NCGC]
MLPCN Grant: 1R03MH084827-01
Assay Submitter (PI): Tom Misteli

Alternative splicing of pre-mRNAs plays a major role in the regulation of eukaryotic gene expression. Alternative splicing is now thought to be one of the primary reasons for the complexity of higher organisms leading to an average of three protein isoforms per gene. Aberrant splicing can lead to a number of diseases and is known to play a role in rare genetic diseases such as progeria syndrome. Hutchinson-Gilford Progeria Syndrome (HGPS) is a pediatric premature aging disease caused by a spontaneous mutation in the lamin A/C (LMNA) gene due to a single point mutation in the lamin A gene effecting 1 in 4 million people (1).
To identify both specific splicing modulators of the lamin A gene as well as general splicing modulators, a cell-based HTS assay was developed using a minigene reporter system (AIDs, 1459 & 1487). A quinazoline (CID: 16759567) showed weak activity as an inhibitor of aberrant splicing using the minigene reporter system (AID 1498). A preliminary kinase profile of this compound showed activity in splicing related kinases belonging to the CDC-like kinase (Clk) family particularly the Clk4. This AID summarizes the characterization of Clk4 inhibitors in three different assays and a protein kinase selectivity panel.
The quinazoline compound (CID_3232621, ML106) and the pyrimidine compound (CID_3234998, ML105) inhibit Clk4 with an IC50 = 0.06 uM. Inhibition was confirmed using purified Clk4 (Invitrogen, CA) employing three different assays: fluorescent polarization based detection of the ADP product (AID 1983), bioluminescent detection of ATP depletion (AID 1970), and bioluminescent detection of the ADP product (AID 1969; for further description of the bioluminescent assays see ref 1). Selectivity against other protein kinases was determined at Ambit Biosciences against 417 kinases. We also submitted TG003 to Ambit, which is the only other small molecule reported to inhibit Clk4 with a similar potency (2). TG003 was determined to have Kds of 19 nM, 95 nM, and 30 nM versus Clk1, Clk2, and Clk4, respectively. The Kd for TG003 versus Clk3 was 3 uM. It was also found that TG003 had activity versus CSNK1D (150 nM), CSNK1E (300 nM), Dyrk1A (12 nM), Dyrk1B (130 nM), PIM1 (130 nM), PIM3 (280 nM), and 170 Ysk4 (290 nM). The novel quinazoline CID 3232621 was found to have Kds of 37 nM, 50 nM and 27 nM versus Clk1, Clk4, and Dyrk1A, respectively. The only other locus of relevant activity (below 500 nM) was found for binding to the endothelial growth factor receptor (EGFR) (Kd = 230 nM; see ref 3).

A new probe compound (CID: 44968231, ML167) inhibits Clk4 with an IC50 = 0.14uM was identified later, it is selective against a panel of these related kinases: Clk1, 2 & 3, DYRK1/DYRK1A, and DYRK1B.
Protocol
Please refer to other AIDs (1459, 1487, 1498, 1770, 1771, 1795, 1969, 1970, 1983, 2705 and 2710) for detailed assay protocols.
Comment
This summary is written for the purposes of summarizing the activities of the chemical probe, identified in this project. MLSCN probes are given a score of 100. Less active molecules in the same chemical series as the probe molecules are given a score of 50.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1ML#Molecular library probe numberString
2PhenotypeIndicates type of activity observed based on the compound activity across various assays tested.String
3Potency ATP depletion_Clk4The concentration of sample yielding half-maximal inhibition in Kinase-glo assay in detection of ATP depletion.FloatμM
4Potency ADP formation_Clk4The concentration of sample yielding half-maximal inhibition in ADP-glo assay in detection of ADP product.FloatμM
5Potency ADP-FP_Clk4The concentration of sample yielding half-maximal inhibition in ADP-FP assay in fluorescent polarization based detection of the ADP product.FloatμM
6Potency ATP depletion_Dyrk1aThe concentration of sample yielding half-maximal inhibition for Dyrk1a in Kinase-glo assay in detection of ATP depletion.FloatμM
7Potency_RB_Clk4The concentration of sample yielding half-maximal inhibition for Clk4 in Reaction Biology panel assay.FloatμM
8Potency_RB_Clk1The concentration of sample yielding half-maximal inhibition for Clk1 in Reaction Biology panel assay.FloatμM
9Potency_RB_Clk2The concentration of sample yielding half-maximal inhibition for Clk2 in Reaction Biology panel assay.FloatμM
10Potency_RB_Clk3The concentration of sample yielding half-maximal inhibition for Clk3 in Reaction Biology panel assay.FloatμM
11Potency_RB_Dyrk1aThe concentration of sample yielding half-maximal inhibition for Dyrk1a in Reaction Biology panel assay.FloatμM
12Potency_RB_Dyrk1bThe concentration of sample yielding half-maximal inhibition for Dyrk1b in Reaction Biology panel assay.FloatμM
Additional Information
Grant Number: 1R03MH084827-01

Data Table (Concise)
Classification
PageFrom: